Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook
More News

HIV-1 Genotyping System Premarket Notification Submitted to FDA

Facebook Twitter LinkedIn Email Comments
ALAMEDA, Calif., August 1 -— Celera Diagnostics, a joint venture of Applied Biosystems Group and Celera Genomics Group, both Applera Corporation businesses, announced that a 510(k) Premarket Notification has been submitted to the US Food and Drug Administration (FDA) seeking marketing clearance of the ViroSeq HIV-1 Genotyping System as an in vitro diagnostic product. This submission was filed by Applied Biosystems.

Pending receipt of marketing clearance from the FDA, Applied Biosystems will have marketing responsibility for the product. The FDA has advised that the submission has been received and assigned a reference number. Celera Diagnostics and Applied Biosystems expect to work closely with the FDA to follow the accelerated de novo review process of the FDA Modernization Act of 1997 for the clearance of low-risk, class II devices, which have no substantially equivalent predicate device already on the market.

The ViroSeq system is designed to detect drug resistance in the HIV-1 virus genome. "The HIV-1 virus mutates rapidly, which greatly compromises the efficacy of drug regimens," said Eric D. Shulse, director of molecular diagnostics at Celera Diagnostics. "We believe that genotyping with the ViroSeq HIV-1 Genotyping System will be a useful tool in identifying drug resistance in the HIV-1 genome. With this information, physicians could in the future be able to prescribe treatment regimens that might be precisely tailored to the type of HIV-1 drug-resistant strain infecting the patient."


Photonics.com
Aug 2001
News & Features

Comments
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2020 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, info@photonics.com

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.